Glioblastoma Companies

Top Industry Leaders in the Glioblastoma Market

Glioblastoma Key Companies Latest Glioblastoma Companies Update

October 2023: A investigator-initiated study, supported by the Ben & Catherine Ivy Foundation and Barrow Neurological Foundation, has effectively combined AstraZeneca-provided radiation therapy with the Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD1390 in the treatment of recurrent glioblastoma. The institute released preliminary findings from a phase 0/1 clinical trial of AZD1390 in combination with radiation therapy for recurrent glioblastoma. The study provided novel human evidence that AZD1390 could potentially function as a potent radiosensitizer in glioblastoma patients. It appears that tissue selectivity and blood-brain barrier penetration were the primary obstacles, but as in this study, contemporary approaches continue to attempt to overcome these challenges.

June 2023: Chimeric Therapeutics initiated a new Phase IB clinical trial for CHM 1101 (CLXT CAR T) cell therapy, which is designed to treat glioblastoma multiforme patients who have recurrent or progressive disease. The safety and efficacy of CHM 1101 in patients with the most lethal form of primary brain cancer will be assessed in this study. The recommended Phase II dose is determined by the two-part Phase IB study, which consists of Part A and Part B. Three to six patients will be enrolled in Part A of the study while the City of Hope Cancer Centre determines the optimal dose. Part B will include an additional twelve to twenty-six patients. Late this year, Chimeric will also assess the activity and safety of the CHM 1101 clinical program. The utilization of multiple clinical trial sites for recruitment in this multi-center trial will expedite the development of CHM 1101. Furthermore, should the clinical results support this, it will also position us to accelerate the subsequent phase of development.

List of Glioblastoma Key companies in the market